Persistent memory B cell down-regulation after 6-year remission induced by rituximab therapy in patients with systemic lupus erythematosus

Lupus

Volumn 22, Issue 5, 2013, Pages 538-540

  Iwata, S ^a   Saito, K ^a   Tokunaga, M ^a   Tanaka, Y ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD19 ANTIGEN; CD27 ANTIGEN; CD40 LIGAND; CD45RO ANTIGEN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN D; IMMUNOGLOBULIN RECEPTOR; RITUXIMAB;

ANTIGEN EXPRESSION; B LYMPHOCYTE; B LYMPHOCYTE DIFFERENTIATION; CD4+ T LYMPHOCYTE; CELL INTERACTION; CLINICAL ARTICLE; CORTICOSTEROID THERAPY; DOWN REGULATION; DRUG DOSE REDUCTION; DRUG MEGADOSE; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; IMMUNOSUPPRESSIVE TREATMENT; LETTER; LONG TERM CARE; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOMA; MEMORY CELL; NEUROPSYCHIATRIC SYSTEMIC LUPUS ERYTHEMATOSUS; PATHOGENESIS; PLASMA CELL; PRIORITY JOURNAL; REMISSION; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TREATMENT DURATION;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD19; B-LYMPHOCYTE SUBSETS; DOWN-REGULATION; HUMANS; IMMUNOLOGIC MEMORY; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE DEPLETION; REMISSION INDUCTION;

EID: 84875964483     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203313477899     Document Type: Letter

References (10)

1. Looney RJ, Anolik JH, Campbell D, et al. B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose-escalation trial of rituximab. Arthritis Rheum. 2004 ; 50: 2580-2589
2. Leandro MJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum. 2002 ; 46: 2673-2677
3. Rastetter W, Molina A, White CA. Rituximab: Expanding role in therapy for lymphomas and autoimmune diseases. Annu Rev Med. 2004 ; 55: 477-503
4. Anolik J, Sanz I, Looney RJ. B cell depletion therapy in systemic lupus erythematosus. Curr Rheumatol Rep. 2003 ; 5: 350-356
5. Tanaka Y, Yamamoto K, Takeuchi T, et al. A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus. Mod Rheumatol. 2007 ; 17: 191-197
6. Tokunaga M, Fujii K, Saito K, et al. Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab. Rheumatology (Oxford). 2005 ; 44: 176-182
7. Tokunaga M, Saito K, Kawabata D, et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis. 2007 ; 66: 470-475
8. Lu TY, Ng KP, Cambridge G, et al. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthritis Rheum. 2009 ; 61: 482-487
9. Iwata S, Saito K, Tokunaga M, et al. Phenotypic changes of lymphocytes in patients with systemic lupus erythematosus who are in long-term remission after B cell depletion therapy with rituximab. J Rheumatol. 2011 ; 38: 633-641
10. Weller S, Braun MC, Tan BK, et al. Human blood IgM "memory" B cells are circulating splenic marginal zone B cells harboring a prediversified immuno- globulin repertoire. Blood. 2004 ; 104: 3647-3654